Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective.
Saved in:
| Title: | Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective. |
|---|---|
| Authors: | Taskar KS; Drug Metabolism and Pharmacokinetics, IVIVT, GlaxoSmithKline, Stevenage, UK., Yang X; Office of Clinical Pharmacology, Center of Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA., Neuhoff S; Certara UK Ltd., Simcyp Division, Sheffield, UK., Patel M; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA., Yoshida K; Clinical Pharmacology, Genentech Early Research and Development, South San Francisco, California, USA., Paine MF; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA., Brouwer KLR; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Chu X; Department of ADME and Discovery Toxicology, Merck & Co., Inc., Kenilworth, New Jersey, USA., Sugiyama Y; Laboratory of Quantitative System PK/Pharmacodynamics, School of Pharmacy, Josai International University, Tokyo, Japan., Cook J; Clinical Pharmacology, Global Product Development, Pfizer Inc., Groton, Connecticut, USA., Polli JW; Global Medical Sciences, ViiV Healthcare, Research Triangle Park, North Carolina, USA., Hanna I; Pharmacokinetic Sciences-Oncology, Novartis Institute for Biomedical Research, East Hanover, New Jersey, USA., Lai Y; Drug Metabolism, Gilead Sciences Inc., Foster City, California, USA., Zamek-Gliszczynski M; Drug Metabolism and Pharmacokinetics, IVIVT, GlaxoSmithKline, Upper Providence, Pennsylvania, USA. |
| Corporate Authors: | ITC |
| Source: | Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2022 Sep; Vol. 112 (3), pp. 573-592. Date of Electronic Publication: 2022 Jun 22. |
| Publication Type: | Journal Article; Review; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 35612761 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Taskar+KS%22">Taskar KS</searchLink>; Drug Metabolism and Pharmacokinetics, IVIVT, GlaxoSmithKline, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Yang+X%22">Yang X</searchLink>; Office of Clinical Pharmacology, Center of Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Neuhoff+S%22">Neuhoff S</searchLink>; Certara UK Ltd., Simcyp Division, Sheffield, UK.<br /><searchLink fieldCode="AU" term="%22Patel+M%22">Patel M</searchLink>; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Yoshida+K%22">Yoshida K</searchLink>; Clinical Pharmacology, Genentech Early Research and Development, South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Paine+MF%22">Paine MF</searchLink>; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.<br /><searchLink fieldCode="AU" term="%22Brouwer+KLR%22">Brouwer KLR</searchLink>; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Chu+X%22">Chu X</searchLink>; Department of ADME and Discovery Toxicology, Merck & Co., Inc., Kenilworth, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Sugiyama+Y%22">Sugiyama Y</searchLink>; Laboratory of Quantitative System PK/Pharmacodynamics, School of Pharmacy, Josai International University, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Cook+J%22">Cook J</searchLink>; Clinical Pharmacology, Global Product Development, Pfizer Inc., Groton, Connecticut, USA.<br /><searchLink fieldCode="AU" term="%22Polli+JW%22">Polli JW</searchLink>; Global Medical Sciences, ViiV Healthcare, Research Triangle Park, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Hanna+I%22">Hanna I</searchLink>; Pharmacokinetic Sciences-Oncology, Novartis Institute for Biomedical Research, East Hanover, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Lai+Y%22">Lai Y</searchLink>; Drug Metabolism, Gilead Sciences Inc., Foster City, California, USA.<br /><searchLink fieldCode="AU" term="%22Zamek-Gliszczynski+M%22">Zamek-Gliszczynski M</searchLink>; Drug Metabolism and Pharmacokinetics, IVIVT, GlaxoSmithKline, Upper Providence, Pennsylvania, USA. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22ITC%22">ITC</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220372741%22">Clinical pharmacology and therapeutics</searchLink> [Clin Pharmacol Ther] 2022 Sep; Vol. 112 (3), pp. 573-592. <i>Date of Electronic Publication: </i>2022 Jun 22. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Review; Research Support, N.I.H., Extramural – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0372741 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1532-6535 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200099236%22">00099236 </searchLink><i>NLM ISO Abbreviation: </i>Clin Pharmacol Ther <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35612761 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/cpt.2670 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 573 Titles: – TitleFull: Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Taskar KS – PersonEntity: Name: NameFull: Yang X – PersonEntity: Name: NameFull: Neuhoff S – PersonEntity: Name: NameFull: Patel M – PersonEntity: Name: NameFull: Yoshida K – PersonEntity: Name: NameFull: Paine MF – PersonEntity: Name: NameFull: Brouwer KLR – PersonEntity: Name: NameFull: Chu X – PersonEntity: Name: NameFull: Sugiyama Y – PersonEntity: Name: NameFull: Cook J – PersonEntity: Name: NameFull: Polli JW – PersonEntity: Name: NameFull: Hanna I – PersonEntity: Name: NameFull: Lai Y – PersonEntity: Name: NameFull: Zamek-Gliszczynski M IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 09 Text: 2022 Sep Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1532-6535 Numbering: – Type: volume Value: 112 – Type: issue Value: 3 Titles: – TitleFull: Clinical pharmacology and therapeutics Type: main |
| ResultId | 1 |